Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2012

View Archived Issues

Sanofi reviews progress of 2011

New serotonin receptor antagonist shows promise to treat cognitive deficiencies

German study reveals new prognostic marker for penile cancer

Boehringer Ingelheim presents new therapeutic candidates for hepatitis C

New B-raf inhibitors developed by Nerviano Medical Sciences

AstraZeneca reports novel potential cancer therapies

New candidate schizophrenia therapeutics developed in Japan

Merck & Co. research yields novel anti-infectives

New multifuctional pactamycin analogues synthesized in U.S.

Novavax kicks off phase II trial of quadrivalent flu vaccine

Tekmira Pharmaceuticals adds new RNAi therapeutic to pipeline

Proximagen VAP-1 inhibitor enters phase I study

Galapagos receives milestones payments in osteoarthritis alliance

Urinary biomarker may be useful to detect and monitor kidney damage

Ablynx provides pipeline update

Arena Pharmaceuticals files MAA for weight control drug

Phosphagenics and Nippon Zoki sign prelicensing agreement

Second milestone reached in Ipsen/Photocure collaboration

SK Biopharmaceuticals obtains funding for lead program in refractory epilepsy

FDA approves two Aptalis Pharma pancrelipase products

First-in-human study of implantable drug delivery microchip succeeds

New PEGylated G-CSF conjugates developed to treat neutropenia

Merck & Co. describes novel vaccines

New study investigates cabozantinib combined with abiraterone

Aegerion files applications for cholesterol-lowering agent in U.S. and E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...